NASDAQ$INGN

Inogen Inc · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Inogen's financial performance declined due to supply chain constraints, but direct-to-consumer and international revenues increased.

Inogen reported a decrease in total revenue by 7.5% compared to Q1 2021, primarily due to supply chain constraints. However, the company saw growth in domestic direct-to-consumer revenue and international business-to-business revenue. The company reported a net loss of $14.2 million, or $0.62 per diluted share.

  • Total revenue decreased by 7.5% year-over-year to $80.4 million due to supply chain constraints.
  • Domestic direct-to-consumer revenue increased by 12.2% to $34.4 million.
  • International business-to-business revenue increased by 77.7% to $27.9 million.
  • GAAP loss per diluted share was $0.62, compared to a loss of $0.03 in Q1 2021.

Headline financials

Total Revenue

$80.4M

Previous: $86.9M-7.5%
EPS (adj)

-$0.39

Previous: -$0.03-1200.0%
Capital Expenditures

-$1.37M

Previous: -$1.52M+9.9%
Free Cash Flow

-$15.6M

Previous: -$2.25M-593.1%
Net Income

-$14.2M

Previous: -$732K-1841.8%
Operating Income

-$13.6M

Previous: -$2.13M-537.2%
Gross Profit

$35M

Previous: $39.9M-12.2%
Cash & Equivalents

$213M

Previous: $220M-3.0%
Total Assets

$475M

Previous: $476M-0.4%
Stock-Based Comp

$2.67M

Previous: $2.52M+5.9%

Revenue & EPS history

Inogen · Revenue · Quarterly

$80.4M

Q1 2022-7.5%vs Q1 2021
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Forward guidance

Inogen expects total revenue for the second quarter of 2022 to improve sequentially and to be in line with the same period in 2021. The Company expects gross margin percentage for the second quarter of 2022 to be in line with the first quarter of 2022, as higher selling prices are offset by continued cost pressure. For the second quarter and full year of 2022, the Company expects losses in Adjusted EBITDA and earnings per diluted share resulting from continued investment in the business.

Tailwinds

  • Total revenue for Q2 2022 expected to improve sequentially.
  • Total revenue for Q2 2022 expected to be in line with the same period in 2021.
  • Gross margin percentage for Q2 2022 expected to be in line with Q1 2022.
  • Higher selling prices offsetting continued cost pressure.
  • Significant investments in clinical research, research and development, and commercial operations.

Headwinds

  • Ongoing uncertainty related to the COVID-19 pandemic.
  • Supply chain disruptions, including the war in Ukraine.
  • COVID-19 lockdown in China potentially impacting the second half of the year.
  • Continued higher material costs associated with open-market purchases of semiconductor chips.
  • Expected losses in Adjusted EBITDA and earnings per diluted share for Q2 and full year 2022.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

-0.7%

Avg return

Earnings day

-2.0%

Avg return

5 days after

-2.0%

Avg return

30 days after

49%

26 / 53 earnings

Positive

+35.5%

Q2 2024

Best reaction

-32.2%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.4%-5.3%-11.0%
Q4 2025+4.3%+5.8%+6.0%
Q3 2025-0.6%+0.9%-1.3%
Q1 2025-11.5%-14.4%-8.1%
Q4 2024-14.8%-14.6%-28.6%
Q3 2024+15.9%+9.1%-0.7%
Q2 2024+35.5%+50.6%+43.0%
Q1 2024+14.6%+17.7%+17.7%
Q4 2023-32.2%-24.3%-13.0%
Q3 2023-1.3%-8.1%+10.0%
Q2 2023-14.6%-18.7%-20.8%
Q1 2023-6.1%-19.3%-21.9%
Q4 2022-31.4%-32.4%-46.4%
Q3 2022-12.5%-10.0%-0.8%
Q2 2022-6.9%-7.3%-6.3%
Q1 2022-2.2%-7.8%+2.0%
Q4 2021+12.6%+25.3%+13.5%
Q3 2021-6.0%-7.3%-21.6%
Q2 2021-22.8%-16.8%-22.1%
Q1 2021-3.5%-2.4%-12.8%
Q4 2020+4.6%+5.4%-4.2%
Q3 2020-7.1%+9.8%+33.0%
Q2 2020+16.4%+17.0%-6.5%
Q1 2020-21.4%-20.1%-24.2%
Q4 2019+10.2%+5.4%+26.4%
Q3 2019+17.3%+19.7%+24.4%
Q2 2019-15.4%-18.5%-20.9%
Q1 2019-28.8%-22.2%-31.8%
Q4 2018-26.4%-25.9%-35.1%
Q3 2018-18.8%-22.6%-24.8%
Q2 2018+7.7%+6.3%+21.3%
Q1 2018+21.0%+18.7%+26.7%
Q4 2017-9.3%-8.4%-7.8%
Q3 2017+16.1%+12.9%+15.0%
Q2 2017-5.6%-3.9%+0.3%
Q1 2017+0.2%-2.6%+11.9%
Q4 2016+6.8%+6.0%+11.4%
Q3 2016+13.0%+15.8%+22.3%
Q2 2016+0.9%+9.3%+8.9%
Q1 2016-6.6%
Q4 2015+20.6%
Q3 2015-1.8%
Q2 2015+13.0%
Q1 2015+4.9%
Q4 2014+1.8%
Q4 2012+1.8%
Q3 2013-1.7%
Q3 2014+6.0%
Q2 2014+3.6%
Q2 2013+3.6%
Q1 2013+12.7%
Q1 2014+12.7%
Q4 2013-1.0%
Q3 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro